BioAdaptives, Inc. (OTC: BDPT) has detailed the scientific strategy behind its Xcellara™ cellular wellness platform as the company prepares for the planned August 1 commercial launch of XcellaraHeart™. The platform integrates a stem/progenitor cell mobilization base, which has been validated by a human randomized controlled trial showing an average 268.8% increase in circulating stem/progenitor-type cells, with tissue-specific ingredients that support the body’s natural signaling pathways to direct those cells to targeted areas.
XcellaraHeart, the first commercial application of the platform, pairs the Xcellara base with Tanshinone IIA, a compound derived from Danshen that has been studied for its role in cardiovascular SDF-1α/CXCR4 signaling. BioAdaptives plans to expand the platform with additional formulas targeting wellness categories including joint mobility, skin health, cognitive wellness, and metabolic resilience, using the same supply-and-direction development model.
According to the press release, the company emphasizes that the Xcellara base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters. The Xcellara product line currently includes seven targeted formulas that combine this clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications.
The complete scientific evidence dossier for the XcellaraHeart formulation will be available at products.xcellara.com/science. The dossier separates findings demonstrated in BioAdaptives’ human clinical research on the Xcellara base from published research on Tanshinone IIA and from the company’s product-development rationale for combining the two.
This announcement underscores BioAdaptives’ commitment to a science-driven approach in the dietary supplement market, potentially setting a new standard for products aimed at supporting cellular health and targeted wellness. The platform’s ability to mobilize stem cells and direct them to specific tissues could have significant implications for various health applications, pending further research and consumer adoption.
